European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up. (LUMIFOLLOW)

The objective of this all-comers registry is to explore the safety, efficacy, and cost-efficiency of the LUMINOR© DEB in de-novo and restenotic-FP lesions. For de-novo and restenotic lesions, especially for calcified and/or long lesions/occlusions, the use of debulking devices to improve recalibration and drug penetration will be evaluated in a specific sub-group.

Study Overview

• Status: Recruiting
• Conditions: Peripheral Arterial Disease; Angioplasty; Paclitaxel; Drug-eluting Balloon; Femoral Artery
• Intervention / Treatment: Device: LUMINOR© Paclitaxel eluting balloon

• Study Type: Observational
• Enrollment (Anticipated): 500

Contacts and Locations

Study Locations

• France
  • Annecy, France, 74000
    • Recruiting
    • Clinique Générale Annecy
    • Contact: Laurence Destrieux, Dr; Phone Number: 33662364432; Email: laurence.destrieux@yahoo.com
  • Avignon, France, 84000
    • Recruiting
    • Clinique Rhône Durance
    • Contact: Jérôme Brunet, Dr.; Phone Number: 33663809865; Email: jeromebrunet2@wanadoo.fr
  • Bayonne, France, 64100
    • Recruiting
    • Centre Hospitalier de la Côte Basque
    • Contact: Laurent Lagoarde, Dr; Phone Number: 33611189298; Email: mailto:llagoarde-segot@ch-cotebasque.fr
  • Bordeaux, France, 33300
    • Recruiting
    • Polyclinic Bordeaux Nord Aquitaine
    • Contact: Dominique Biscay, Dr; Phone Number: 33556437017; Email: dr.biscay@gmail.com
  • Boulogne-Billancourt, France, 92100
    • Recruiting
    • Hôpital Ambroise Paré
    • Contact: Raphael Coscas, Pr; Phone Number: 33149095585; Email: raphael.coscas@aphp.fr
  • Brest, France, 29200
    • Recruiting
    • Centre Hospitalier Régional Universitaire Morvan de Brest
    • Contact: Bahaa Nasr, Dr; Phone Number: 33612116346; Email: bahaa.nasr@chu-brest.fr
  • Lille, France, 59000
    • Recruiting
    • CHRU Lille
    • Contact: Jonathan Sobocinski, Pr; Phone Number: 33665902150; Email: jonathan.sobocinski@chru-lille.fr
  • Lorient, France, 56100
    • Recruiting
    • Clinic Mutualiste Porte de L'Orient
    • Contact: Jean Baptiste Bocquel, Dr; Phone Number: 33688817794; Email: jean-baptiste.bocquel@clinique.mutualite56.fr
  • Marseille, France, 13005
    • Recruiting
    • CHU Timone MARSEILLE
    • Contact: Michel Alain Bartoli, Pr; Phone Number: 33491385762; Email: michelalain.bartoli@ap-hm.fr
  • Mont-de-Marsan, France, 40024
    • Recruiting
    • CH Layne
    • Contact: Mathieu Poirier, Dr; Phone Number: 33661901257; Email: mathieu.poirier@ch-mdm.fr
  • Nîmes, France, 30000
    • Recruiting
    • Hôpital Privé des Franciscaines
    • Contact: Nicolas Louis, Dr; Phone Number: 33671241324; Email: drlouisnicolas@yahoo.fr
  • Paris, France, 75014
    • Recruiting
    • Fondation Hôpital St Joseph
    • Contact: Yann Goueffic, Pr; Phone Number: 33625781753; Email: ygoueffic@ghpsj.fr
  • Saint-Jean-de-Védas, France, 34430
    • Recruiting
    • Clinique Saint Jean
    • Contact: Benjamin Thévenin, Dr.; Phone Number: 33789003025; Email: thevenin.benjamin@hotmail.fr
  • Strasbourg, France, 67000
    • Recruiting
    • Clinique Rhena
    • Contact: Gilles Goyault, Dr; Phone Number: 33680330596; Email: gillesgoyault@gmail.com
  • Nouvelle-Aquitaine
    • Bordeaux, Nouvelle-Aquitaine, France, 33000
      • Recruiting
      • Centre hospitalier universitaire Pellegrin
      • Contact: Eric Ducasse, Pr; Phone Number: 33609835704; Email: eric.ducasse@chu-bordeaux.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with peripheral artery disease due to occlusive lesions, stenosis of ingraguinal arteries and restenosis after previous angioplasty with/without stent in that sector.

Description

Inclusion Criteria:

• ≥ 18 years of age
• Rutherford Clinical Category 2-5
• The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study, voluntarily agrees to participation, is willing to provide 5-year informed consent and has duly signed the informed consent form (ICF)
• Significant (≥ 70%) stenosis or occlusion of a native femoropopliteal artery
• TASC II Class A to D Lesions
• de novo lesion(s), non-stented or stented restenotic lesion(s)
• Proximal margin of target lesion(s) starts at the ostium of the superficial femoral artery, just below the common femoral bifurcation
• Distal margin of target lesion(s) terminates at bifurcation of popliteal artery AND ≥1 cm above the origin of the TP trunk (P3)
• A patent inflow artery free from significant lesion (≥ 50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of iliac or common femoral inflow artery lesions); Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤ 30% without death or major vascular complication
• Successful wire crossing and pre-dilatation (1min min, with under sizing of 1mm compared to ref diameter) of the target lesion; Use of crossing devices allowed if necessary. Use of laser or atherectomy is allowed if necessary, during the index procedure. Bailout stenting is allowed if necessary, after DEB use
• At least one patent native outflow artery to the ankle, free from significant (≥ 50%) stenosis as confirmed by angiography (treatment of outflow disease is NOT permitted during the index procedure)

Exclusion Criteria:

• Women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children
• Patient is contraindicated to use Luminor Drug Eluting Balloon per the current Instructions For Use (IFU)
• Life expectancy of < 1year
• Patient is currently participating in an investigational drug or other device study or previously enrolled in this study
• Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication
• Sudden symptom onset, acute vessel occlusion, or acute or sub-acute angiographically visible thrombus in target vessel

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
LUMINOR© drug eluting balloon	Device: LUMINOR© Paclitaxel eluting balloon; Patients will be treated with the Luminor paclitaxel eluting balloon

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Endpoint Efficacy measured by presence of primary patency of the target lesion based on ultrasound images	Primary Patency is defined as Freedom from Clinically-Driven Target Lesion Revascularization and from Binary Restenosis.	12 Months
Overall Medical Safety	Combination assessment of freedom from all-cause peri-procedural (≤30 day) death and freedom at 3 years from the following: index limb amputation (above or below the ankle), and all-cause mortality (with a detailed analysis of cardiovascular (CV) and non-CV deaths). Success is defined as freedom from all specified events; failure is defined as one or more specified events occurrences.	36 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Endpoint Efficacy: Acute Device Success	Device success is defined as, a per device basis, the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system. If a device is inserted into the subject but not used due to user error (e.g. inappropriate balloon length or transit time too long), this device will not be included in the device success assessment.	During index procedure
Secondary Endpoint Efficacy: Technical Success	Technical Success of the balloon procedure is defined as successful access and deployment of the device and visual estimate of ≤ 30% diameter residual stenosis during the index procedure.	During index procedure
Secondary Endpoint Medical Safety: Major vascular complications	Major vascular complications will be counted: Haematoma at access site >5 cm; False aneurysm; AV fistula; Retroperitoneal bleeding; Peripheral ischemia/nerve injury; Any transfusion required will be reported as a vascular complication unless clinical indication clearly other than catheterization complication; Vascular surgical repair	≤30 days after index procedure
Secondary Endpoint Medical Safety: Composite Safety	Combination assessment of freedom from all-cause death and freedom from the following: index limb amputation (above or below the ankle = major or minor amputation) and index limb re-intervention. Success is freedom from all specified events; failure is occurrence of one or more specified events.	1, 6, 12, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: All-cause death	Death by any cause will be counted and stratified between CV and non-CV deaths. Cause of death will be analyzed to search for any specific increase of a death's subtype.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Major amputation at target limb	Amputations above the ankle of the target leg will be counted. Optional histologic examination of fixed muscle segments in 10% neutral-buffered formalin could be performed in the Inserm unit 1034, Pessac, France to search for paclitaxel microparticle deposits, fibrinoid necrosis artery wall injury, inflammation, thrombus, hemorrhage, and fibrosis. Adjacent nonfixed samples of similar distal tissues, flash-frozen in liquid nitrogen, and retained at -80°C will be used for bioanalysis of paclitaxel levels by modified liquid chromatography/tandem mass spectroscopy.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Minor amputation at target limb	Amputations below the ankle of the target leg will be counted.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Target Vessel Revascularization (TVR)	Repeat intervention at the target vessel will be counted.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Target Limb Reintervention	Repeat intervention at the target leg will be counted.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Procedural Success	Attainment of ≤ 30% residual stenosis in the treatment area without major adverse events (defined as occurrence of death, major amputation of the target limb, target vessel or distal revascularization) during the index procedure and through the hospital stay.	Up to 30 days
Secondary Endpoint Efficacy: Primary Patency	Primary Patency is defined as Freedom from Clinically-Driven Target Lesion Revascularization and from Binary Restenosis. Binary restenosis is adjudicated by the validated center based on threshold Doppler PSVR ≥ 2.5 (together with waveform analysis & color mosaic appearance) or based on angiographic ≥ 50% diameter stenosis (if angiography is performed although not required per protocol).	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Secondary Patency	Secondary Patency of the target lesion is defined as the absence of binary restenosis as adjudicated by the validated center, independent of whether or not patency is re-established via an endovascular procedure.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Clinically-driven Target Lesion Revascularization (TLR)	Revascularization of the target lesion with evidence of diameter stenosis >50% determined by duplex ultrasound or angiography and new distal ischemic signs (worsening ABI or worsening Rutherford Category associated with the target limb or due to clinical symptoms).	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Target Lesion Revascularization (TLR)	A repeat revascularization procedure (percutaneous or surgical) of the original target lesion site.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change of Rutherford classification from baseline	Patients are enrolled with a Rutherford grade of 2-5 for their target leg. The Rutherford scale is an indicator for the severity of Peripheral Vascular Disease: 0 = no symptoms, 6 = functional foot is no longer salvageable (leading to foot amputation).	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change of resting Ankle Brachial Index (ABI) from baseline	The ABI values will be recorded and compared to the baseline values. The ABI is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. A ratio of 0.9-1.3 is in the normal range. Lower ratios indicate bad blood perfusion of the leg.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change in Walking Impairment Questionnaire from baseline	The Walking Impairment Questionnaire values will be recorded and compared to the baseline values.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change in quality of life from baseline, as measured by EQ-5D	The EQ-5D Questionnaire values will be recorded and compared to the baseline values.	1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Cost-Effectiveness (optional): factoring procedure and hospital admission costs		1, 6, 12, 24, 36, 48, 60 months after index procedure

Collaborators and Investigators

• Sponsor: iVascular S.L.U.

Study record dates

Study Major Dates

• Study Start (Actual): January 18, 2021
• Primary Completion (Anticipated): June 1, 2022
• Study Completion (Anticipated): June 30, 2026

Study Registration Dates

• First Submitted: February 1, 2021
• First Submitted That Met QC Criteria: February 5, 2021
• First Posted (Actual): February 8, 2021

Study Record Updates

• Last Update Posted (Actual): February 11, 2021
• Last Update Submitted That Met QC Criteria: February 10, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Arterial Disease; Peripheral Vascular Diseases; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: LUMIFOLLOW Registry

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No